Technology transfer and business development
One of Biocat’s priorities is to bridge the gap between the innovative potential of the cutting edge research being done in Catalonia and the productive sector and the market. So, we carry out programs that put companies in touch with research groups to address unmet needs and we promote entrepreneurship with training programs and support in putting together and carrying out successful business plans.
A strong, well structured, market oriented transfer system
Technology transfer is one of the most critical areas of action for achieving a highly innovative, competitive and prepared Catalonia. That’s why Biocat analyzes the needs of the Catalan healthcare system and identifies priority areas of innovation to drive projects on an international scale. Additionally, we organize matchmaking activities to promote collaborative relationships among stakeholders in the health ecosystem (researchers, pharma and biotech companies, investors, etc.) and foster agreements between projects at research institutes and hospitals, and potential investors and licensees.
Biocat also works with the Administration and facilitating bodies to establish funding and coordination mechanisms to accelerate project valuation and bring about incentive policies for the research community, doctors, healthcare personnel and innovation managers.
Noteworthy activities
- Periodic meetings with heads of transfer offices (TTO) at Catalonia’s research and knowledge organizations to share experiences and identify needs.
- Matchmaking events for research groups and companies, like the Open Innovation Forum.
- Platforms to help put together early stage projects and investors to drive entrepreneurship and scale up projects, like the Invest BioRegion Portal.
Biocat fosters business opportunities between projects and startups in the BioRegion and corporates
Advanced therapies are drugs for human use based on cells, genes or tissues that regenerate tissue, treat inflammatory and autoimmune diseases and cancer, among other things. The great challenge is going from clinical trials to industry scale up with these therapies.
